Login to Your Account

Expanding Redx Inks Cancer Alliance with Pharmascience

By Nuala Moran
Staff Writer

Tuesday, May 7, 2013

LONDON – Redx Pharma Ltd. has unveiled a shift in strategy away from a sole focus on internally generated compounds, with the in-licensing of an early stage oncology program from Canadian biotech Pharmascience Inc. At the same time Redx announced it has put in place funding for a diversification into anti-infectives and is opening a new unit on the site of AstraZeneca plc's largest R&D facility at Alderley Park, Cheshire, UK.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription